SCHEMBL626599

SCHEMBL626599

C=CC(=O)C=Cc1ccc(O)c(OC)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.82
CYP1A2 P05177 2/20 0.82
ALOX5 P09917 2/20 0.82
NFKB1 P19838 2/20 0.82
HSD11B1 P28845 2/20 0.82
STAT3 P40763 2/20 0.82
NFKB2 Q00653 2/20 0.82
RELA Q04206 2/20 0.82
NFE2L2 Q16236 2/20 0.82
APP P05067 3/20 0.70
KDM4E B2RXH2 2/20 0.70
CA12 O43570 2/20 0.70
CA1 P00915 2/20 0.70
CA2 P00918 2/20 0.70
CA3 P07451 2/20 0.70
PKM P14618 2/20 0.70
CA4 P22748 2/20 0.70
CA6 P23280 2/20 0.70
CA5A P35218 2/20 0.70
SNCA P37840 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626598 1.00 CYP2D6 (0.82) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL29478095 0.91 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL30668505 0.91 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL1493283 0.91 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL1493282 0.91 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL3337939 0.88 CYP1A2 (0.63) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL3337937 0.88 CYP1A2 (0.63) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL29428460 0.88 KDM4E (0.69) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL2744234 0.86 CYP2D6 (0.91) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL2744233 0.86 CYP2D6 (0.91) CYP2D6CYP1A2ALOX5NFKB1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054365-A2 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES Uniban - Universidade Bandeirante De São Paulo (BR) 2009-05-06 EP claimed
WO-2008003155-A2 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES UNIBAN - UNIVERSIDADE BANDEIRANTE DE SÃO PAULO - ACADEMIA PAULISTA ANCHIETA S/C LTDA (BR) 2008-01-10 WO claimed
CN-114478256-A Preparation method of novel curcumin derivative and application of novel curcumin derivative in resisting liver cancer 安徽理工大学环境友好材料与职业健康研究院(芜湖) 2022-05-13 CN disclosed
EP-2441452-A1 PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS Universidade Bandeirante De São Paulo - Academia Paulista Anchieta S/C Ltda (BR) 2012-04-18 EP disclosed
US-20120082703-A1 PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS UNIVERSIDADE BANDEIRANTE DE SAO PAULO-ACADEMIA PAULISTA ANCHETA S/C LTDA (BR) 2012-04-05 US disclosed
WO-2012021692-A1 CURCUMIN ANALOGS AND METHODS OF USE THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2012-02-16 WO disclosed
EP-2054365-A2 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES Uniban - Universidade Bandeirante De São Paulo (BR) 2009-05-06 EP disclosed
WO-2008003155-A2 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES UNIBAN - UNIVERSIDADE BANDEIRANTE DE SÃO PAULO - ACADEMIA PAULISTA ANCHIETA S/C LTDA (BR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082703-A1 PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS BRCA1, TSG101, POLN CYP2D6 1087/4885CYP1A2 1246/4885ALOX5 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.